MedTrace Logo

Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

NCT01796821 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2020-02-05

No results posted yet for this study

Summary

To evaluate the efficacy of SR-T100 gel by observing total clearance rate of treated baseline EGW(s) on the treated area.

Conditions

  • Condyloma Acuminata
  • Genital Warts
  • Condylomata Acuminata
  • Venereal Warts

Interventions

DRUG

Vehicle gel

Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing. Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing. Total application \<1,500 mg gel per day.

DRUG

SR-T100 gel with 1.0 % SM

Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing. Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing. Total application \<1,500 mg gel per day.

DRUG

SR-T100 gel with 2.3% SM

Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing. Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing. Total application \<1,500 mg gel per day.

Sponsors & Collaborators

  • G&E Herbal Biotechnology Co., LTD

    lead INDUSTRY

Principal Investigators

  • Kou-Wha Kuo, PhD · G&E Herbal Biotechnology Co., LTD

  • Cheng-Yang Chou, M.D. · National Cheng Kung University, Tainan, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2018-09-30
Completion
2018-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796821 on ClinicalTrials.gov